Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Gross Profit: 2010-2024

Historic Gross Profit for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $20,000.

  • Altimmune's Gross Profit changed negligibly% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $20,000, marking a year-over-year decrease of 61.54%. This contributed to the annual value of $20,000 for FY2024, which is 95.31% down from last year.
  • According to the latest figures from FY2024, Altimmune's Gross Profit is $20,000, which was down 95.31% from $426,000 recorded in FY2023.
  • Altimmune's Gross Profit's 5-year high stood at $8.2 million during FY2020, with a 5-year trough of $20,000 in FY2024.
  • For the 3-year period, Altimmune's Gross Profit averaged around $171,333, with its median value being $68,000 (2022).
  • In the last 5 years, Altimmune's Gross Profit plummeted by 98.46% in 2022 and then skyrocketed by 526.47% in 2023.
  • Altimmune's Gross Profit (Yearly) stood at $8.2 million in 2020, then tumbled by 46.12% to $4.4 million in 2021, then tumbled by 98.46% to $68,000 in 2022, then spiked by 526.47% to $426,000 in 2023, then tumbled by 95.31% to $20,000 in 2024.